FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2172406239> ?p ?o ?g. }

• W2172406239 endingPage "675" @default.
• W2172406239 startingPage "656" @default.
• W2172406239 abstract "BackgroundInotropes and vasopressors are frequently administered to critically ill patients in order to improve haemodynamic function and restore adequate organ perfusion. However, some studies have suggested a possible association between inotrope administration and increased mortality. We therefore performed a meta-analysis of randomized trials published in the last 20 yr to investigate the effect of these drugs on mortality.MethodsBioMedCentral, PubMed, Embase and the Cochrane Central Register were searched (all updated April 8th, 2015). Inclusion criteria were: random allocation to treatment, at least one group receiving an inotropic or vasopressor drug compared with at least one group receiving a non-inotropic/vasopressor treatment, study published after 1st January 1994, and systemic drug administration. Exclusion criteria were overlapping populations, studies published as abstract only, crossover studies, paediatric studies and lack of data on mortality.ResultsA total of 28 280 patients from 177 trials were included. Overall, pooled estimates showed no difference in mortality between the group receiving inotropes/vasopressors and the control group [4255/14 036 (31.7%) vs 4277/14 244 (31.8%), risk ratio=0.98 (0.96–1.01), P for effect=0.23, P for heterogeneity=0.30, I2=6%]. A reduction in mortality was associated with inotrope/vasopressor therapy use in settings of vasoplegic syndromes, sepsis and cardiac surgery. Levosimendan was the only drug associated with improvement in survival. Subgroup analysis did not identify any groups with increased mortality associated with inotrope/vasopressor therapy.ConclusionsOur systematic review found that inotrope/vasopressor therapy is not associated with differences in mortality in the overall population and in the majority of subsettings. Inotropes and vasopressors are frequently administered to critically ill patients in order to improve haemodynamic function and restore adequate organ perfusion. However, some studies have suggested a possible association between inotrope administration and increased mortality. We therefore performed a meta-analysis of randomized trials published in the last 20 yr to investigate the effect of these drugs on mortality. BioMedCentral, PubMed, Embase and the Cochrane Central Register were searched (all updated April 8th, 2015). Inclusion criteria were: random allocation to treatment, at least one group receiving an inotropic or vasopressor drug compared with at least one group receiving a non-inotropic/vasopressor treatment, study published after 1st January 1994, and systemic drug administration. Exclusion criteria were overlapping populations, studies published as abstract only, crossover studies, paediatric studies and lack of data on mortality. A total of 28 280 patients from 177 trials were included. Overall, pooled estimates showed no difference in mortality between the group receiving inotropes/vasopressors and the control group [4255/14 036 (31.7%) vs 4277/14 244 (31.8%), risk ratio=0.98 (0.96–1.01), P for effect=0.23, P for heterogeneity=0.30, I2=6%]. A reduction in mortality was associated with inotrope/vasopressor therapy use in settings of vasoplegic syndromes, sepsis and cardiac surgery. Levosimendan was the only drug associated with improvement in survival. Subgroup analysis did not identify any groups with increased mortality associated with inotrope/vasopressor therapy. Our systematic review found that inotrope/vasopressor therapy is not associated with differences in mortality in the overall population and in the majority of subsettings." @default.
• W2172406239 created "2016-06-24" @default.
• W2172406239 creator A5005062164 @default.
• W2172406239 creator A5028927302 @default.
• W2172406239 creator A5048347199 @default.
• W2172406239 creator A5068430114 @default.
• W2172406239 creator A5072968608 @default.
• W2172406239 creator A5073353856 @default.
• W2172406239 creator A5078052999 @default.
• W2172406239 creator A5088912880 @default.
• W2172406239 date "2015-11-01" @default.
• W2172406239 modified "2023-09-30" @default.
• W2172406239 title "The Effect of inotropes and vasopressors on mortality: a meta-analysis of randomized clinical trials" @default.
• W2172406239 cites W1523130600 @default.
• W2172406239 cites W1572336977 @default.
• W2172406239 cites W1579077552 @default.
• W2172406239 cites W1687620054 @default.
• W2172406239 cites W1696255930 @default.
• W2172406239 cites W1749486956 @default.
• W2172406239 cites W1818617568 @default.
• W2172406239 cites W1927489913 @default.
• W2172406239 cites W1946696209 @default.
• W2172406239 cites W1964644822 @default.
• W2172406239 cites W1964843986 @default.
• W2172406239 cites W1965066454 @default.
• W2172406239 cites W1966211381 @default.
• W2172406239 cites W1966775583 @default.
• W2172406239 cites W1969184300 @default.
• W2172406239 cites W1969239465 @default.
• W2172406239 cites W1969928743 @default.
• W2172406239 cites W1970463012 @default.
• W2172406239 cites W1971463126 @default.
• W2172406239 cites W1973204761 @default.
• W2172406239 cites W1976838830 @default.
• W2172406239 cites W1977038205 @default.
• W2172406239 cites W1977257277 @default.
• W2172406239 cites W1979669873 @default.
• W2172406239 cites W1987055208 @default.
• W2172406239 cites W1988345881 @default.
• W2172406239 cites W1988670849 @default.
• W2172406239 cites W1990124149 @default.
• W2172406239 cites W1990867757 @default.
• W2172406239 cites W1991814810 @default.
• W2172406239 cites W1992164618 @default.
• W2172406239 cites W1992630792 @default.
• W2172406239 cites W1994384426 @default.
• W2172406239 cites W1995278635 @default.
• W2172406239 cites W1995449630 @default.
• W2172406239 cites W1999320608 @default.
• W2172406239 cites W1999531750 @default.
• W2172406239 cites W2003135019 @default.
• W2172406239 cites W2003900116 @default.
• W2172406239 cites W2004056437 @default.
• W2172406239 cites W2004623546 @default.
• W2172406239 cites W2004816529 @default.
• W2172406239 cites W2004828123 @default.
• W2172406239 cites W2007366640 @default.
• W2172406239 cites W2007790231 @default.
• W2172406239 cites W2007907197 @default.
• W2172406239 cites W2010699540 @default.
• W2172406239 cites W2011632983 @default.
• W2172406239 cites W2013847400 @default.
• W2172406239 cites W2015222304 @default.
• W2172406239 cites W2016907351 @default.
• W2172406239 cites W2017583766 @default.
• W2172406239 cites W2019228255 @default.
• W2172406239 cites W2019324936 @default.
• W2172406239 cites W2020765940 @default.
• W2172406239 cites W2020954602 @default.
• W2172406239 cites W2021000405 @default.
• W2172406239 cites W2022537218 @default.
• W2172406239 cites W2022670032 @default.
• W2172406239 cites W2023005794 @default.
• W2172406239 cites W2025297946 @default.
• W2172406239 cites W2025754714 @default.
• W2172406239 cites W2026702339 @default.
• W2172406239 cites W2026885542 @default.
• W2172406239 cites W2027960752 @default.
• W2172406239 cites W2028546766 @default.
• W2172406239 cites W2029697114 @default.
• W2172406239 cites W2030088373 @default.
• W2172406239 cites W2031736087 @default.
• W2172406239 cites W2032614454 @default.
• W2172406239 cites W2033164096 @default.
• W2172406239 cites W2034489030 @default.
• W2172406239 cites W2038454936 @default.
• W2172406239 cites W2039922227 @default.
• W2172406239 cites W2043616160 @default.
• W2172406239 cites W2045229306 @default.
• W2172406239 cites W2048373501 @default.
• W2172406239 cites W2049999313 @default.
• W2172406239 cites W2052178607 @default.
• W2172406239 cites W2052715517 @default.
• W2172406239 cites W2054058189 @default.
• W2172406239 cites W2054167248 @default.
• W2172406239 cites W2054473060 @default.
• W2172406239 cites W2054948488 @default.
• W2172406239 cites W2056216337 @default.

• next